UBIGENE

ATRX Knockout cell line (5637)

banner

Red cotton OmniCell bank

10000+
Gene Knockout Cell Lines
2000+
Luc/EGFP/Cas9 Tool Cell Lines
1000+
Wild-type Cell Lines
ATRX Knockout cell line (5637) WB 1490
Copy Product Info
Catalog#
YKO-H518
Species
Human
Target Cell Line
5637
Size
1*10^6
Gene
ATRX
Storage conditions
Shipped on dry ice; Store in liquid nitrogen
iconOnline inquire

Overview

CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.

5637 is a human bladder carcinoma cell line established from a primary bladder tumor of a 68-year-old male patient. The cells are known to produce multiple growth factors, including stem cell factor (SCF), interleukins, and colony-stimulating factors. 5637 cells are used as a model for studying bladder cancer biology, tumor-associated signaling, and growth factor regulation.

Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.

KO Cell Construction Strategy
Adopting Red Cotton CRISPR Gene Editing Designer (www.rc-crispr.com), two sgRNAs targeting the ATRX gene are designed to generate a knockout strategy. The two sgRNA sequences are subsequently cloned into the EZ-editor™ vector and introduced into 5637 cells via electroporation or lentiviral transduction. Single-cell clones are then generated using the limiting dilution method. Genomic DNA from individual clones is subjected to nucleic acid lysis and PCR amplification using the EZ-editor™ Monoclone Genotype Validation Kit (Cat# YK-MV-1000). The edited loci are further verified by Sanger sequencing to confirm the genotype. After secondary validation and quality confirmation, ATRX Knockout cell line (5637) is expanded and cryopreserved for downstream applications.
KO Cell Construction Strategy

Product Overview

ATRX Knockout cell line (5637)
The ATRX Knockout cell line (5637) is generated by targeted disruption of the ATRX gene in 5637 cells. This cell line is designed to investigate the role of ATRX in cellular function and gene regulation, as well as its potential involvement in disease-related pathways.
KO Cell Line
ATRX Knockout cell line (5637)
Gene ID
546
Catalog
YKO-H518
Gene Name
ATRX
Product Category
Knockout(KO) Cell Line
Gene Information
NCBI
Species
Human
Mycoplasma test
Negative
Cell Morphology
Epithelial-like, adherent
Catalog Status
-
Culture method
90%RPMI-1640+10%FBS
Shipping
Cryopreserved Cells shipped in dry ice
Passage ratio
1：2-1：3
Storage Condition
Liquid nitrogen
Quality Control
All KO cell products are tested and confirmed to be free of bacterial, viral, mycoplasma contamination, and other adventitious agents.
Applications
For research use only. Not intended for use in diagnostic, therapeutic, clinical, or other applications.

Key Advantages

Easy to use
Easy to use

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations

High-efficient KO
High-efficient KO

These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.

Curated cells
Curated cells

Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Quality Control Specifications

1. Bacteria and Fungi Test
None Detected.
2. Mycoplasma test
Negative.
3. Knockout Strategy

Knockout Region: E2

Reference Transcript: ATRX-201

Validation Method: PCR amplification+Sanger sequencing

4. STR Authentication
Download STR Report

Intended use

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use

Unpacking and Storage Instructions

1.
Cell Reception
2.
Unpacking and storage instructions

Handling procedure

1.
Cell Thawing
2.
Cell Passaging
3.
Cell cryopreservation

References

More

FAQ

Q1. How to Contact Support if Issues Arise After Receiving the KO Cells?
If any abnormalities are observed after receiving the cells, please provide the following information based on the stage of use and contact us promptly for assistance:
(1) Issues upon delivery: Please provide photos of the cells at the time of receipt along with a brief description of the issue. We will offer after-sales support accordingly.
(2) Issues after thawing or passaging: Please provide microscopic images of the cells before and after thawing/passaging, along with a detailed description of the experimental procedures. Our technical team will provide professional support.
Q2. What Information Is Required When Reporting KO Cell Product Issues?
Q3. How Should the KO cell Product Be Stored Upon Receipt?
Q4. Shipping Method
Q5. Are the Knockout Cell Lines Stable for Passaging? Is Authentication Provided?

Related Popular Products

Wild-type Cell Lines
Human bladder cancer Cell Line (5637)
Catalog#: YC-C102
Product Name: 5637
Instruction:
Size: 1*10^6
Classification: Urinary System
More
KO Cell Lines
ATRX Knockout cell line (U-87 MG) WB 1490
Organism: Human
Gene Name: ATRX
Gene ID: 546
Size: 1*10^6
Catalog#: YKO-H1061
More
ATRX Knockout cell line (MFE-280) WB 1490
Organism: Human
Gene Name: ATRX
Gene ID: 546
Size: 1*10^6
Catalog#: YKO-H1426
More
ATRX Knockout cell line (143B) WB 1490
Organism: Human
Gene Name: ATRX
Gene ID: 546
Size: 1*10^6
Catalog#: YKO-H1158
More

Contact Us

Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours

* Name

* Email

* Institution

* Products & Services of Interest

If email is not available, how else can we reach you?

How did you hear about us?

icon
to-top
Logo
E-mail: info@ubigene.com
WhatsAPP: +86 153 6067 3248
TEL: +86 153 6067 3248(Int'l)
Chat with an Expert
Logo
Logo
Logo
Logo
Logo
Logo
Logo
Copyright © 2025 Ubigene. All rights reserved.
Privacy PolicyImpressum